Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exercise during breast cancer treatment boost fitness and predict response?

NCT ID NCT07799337

Disease control Sponsor: National University of Ireland, Galway, Ireland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether a 14-week physiotherapist-led exercise program, given alongside standard pre-surgery treatment for breast cancer, improves physical fitness, muscle strength, quality of life, and the ability to complete treatment. Researchers will compare participants who exercise with those receiving standard care. The study also looks at whether blood and tumor markers, combined with clinical details, can predict which patients respond best to treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Physiotherapist-led personalised adaptive exercise programme
What this could lead to
If exercise during neoadjuvant therapy improves fitness and quality of life, it could become a standard part of breast cancer care. The study may also identify markers that predict treatment response.
What could go wrong
This is a single trial with 250 participants, and exercise may not improve outcomes for everyone. The predictive markers are exploratory and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older. 2. Histologically confirmed diagnosis of breast cancer. 3. Planned treatment with standard-of-care neoadjuvant systemic therapy. 4. Ability to provide written informed consent. 5. Ability to partake in 14-week physiotherapist-led personalised adaptive exercise programme. 6. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2. Exclusion Criteria: 1. Inability to provide informed consent. 2. Inability to complete patient-reported outcome assessments. 3. Pregnancy. 4. Presence of any condition that, in the opinion of the treating clinician, would preclude participation in study procedures. 5. Inability to partake in 14-week physiotherapist-led personalised adaptive exercise programme.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Breast neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.